A New Flu Shot Debate: The Promise and the Pitfalls of mRNA
The FDA’s advisory panel voted 9‑to‑0 in favor of Moderna’s mRNA flu vaccine for people aged fifty and older. This decision follows a previous rejection that cited incomplete trials, sparking debate over safety and effectiveness. Key Points Phase‑4 Data: A 26.6 % relative boost in protection comp...